Harvard Bioscience (HBIO) Stock Price, News & Analysis

Company Overview

Harvard Bioscience, Inc. develops, manufactures and supplies specialized tools and equipment used in biological, medical and pharmaceutical research. Its products support applications including electrophysiology, cell and tissue research, drug discovery, organ and animal physiology, and laboratory data collection.

The company’s portfolio includes laboratory instruments, systems, consumables and software sold under brands such as Harvard Apparatus, DSI, BTX and Hugo Sachs Elektronik. These products include perfusion and organ-bath systems, stimulation and electroporation equipment, physiological monitoring devices, research sensors, and related laboratory supplies.

Founded in 1901, Harvard Bioscience serves academic institutions, government and research laboratories, biotechnology companies, pharmaceutical manufacturers and medical researchers. The company is headquartered in Holliston, Massachusetts, and distributes its products through direct sales and channel partners in North America, Europe, Asia and other international markets.

Key Stats

• Today's Range: $8.00 to $8.35
• 50-Day Range: $6.13 to $8.56
• 52-Week Range: $3.75 to $9.40
• Volume: 4,014 shs
• Average Volume: 33,872 shs
• Market Capitalization: $36.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.75
• Consensus Rating: Hold

Harvard Bioscience Stock Analysis - MarketRank™

Harvard Bioscience scored higher than 31% of companies evaluated by MarketBeat, and ranked 767th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Harvard Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Downside Risk

Harvard Bioscience has a consensus price target of $6.75, representing about 17.7% downside from its current price of $8.20.

Amount of Analyst Coverage

Harvard Bioscience has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Harvard Bioscience is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harvard Bioscience is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harvard Bioscience has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.19% of the float of Harvard Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Harvard Bioscience has a short interest ratio ("days to cover") of 2.61, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harvard Bioscience has recently decreased by 6.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harvard Bioscience does not currently pay a dividend.

Dividend Growth

Harvard Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Harvard Bioscience has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Harvard Bioscience this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for HBIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.03% of the stock of Harvard Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:HBIO
• CIK: 1123494
• Web: www.harvardbioscience.com
• Phone: (508) 893-8999
• Fax: 508-429-5732
• Employees: 339
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Harvard Bioscience: $6.75
• High Price Target: $7.50
• Low Price Target: $6.00
• Potential Upside/Downside: -16.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.70 million
• Net Margins: -11.86%
• Pretax Margin: -12.01%
• Return on Equity: -33.13%
• Return on Assets: -4.80%

Debt

• Debt-to-Equity Ratio: 4.94
• Current Ratio: 1.87
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $87.81 million
• Price / Sales: 0.42
• Cash Flow: $11.59 per share
• Price / Cash Flow: 0.70
• Book Value: $3.07 per share
• Price / Book: 2.64

Miscellaneous

• Outstanding Shares: 4,552,000
• Free Float: 3,777,000
• Market Cap: $36.94 million
• Optionable: No Data
• Beta: 1.50